Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q1 2021 Earnings Conference Call May 3, 2021 5:00 PM ET Company Participants Daniel Reuvers - President and Chief Executive Officer Brent Moen - Chief Financial Officer Conference Call Participants Andrew Stafford - Piper Sandler & Co. Malgorzata Andrew - William Blair & Company LLC Ryan Zimmerman - BTIG, LLC Christopher Pasquale - Guggenheim Securities, LLC Suraj Kalia - Oppenheimer & Co. Inc. Operator Good evening, ladies and gentlemen, and welcome to the Fir ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q4 2020 Earnings Conference Call February 23, 2021 5:00 PM ET Company Participants Dan Reuvers - President and Chief Executive Officer Brent Moen - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Suraj Kalia - Oppenheimer Operator Good evening ladies and gentlemen, and welcome to the Fourth Quarter and Fiscal Year 2020 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) Delaware (State or o ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2020 was reported at $49.1 million, a decrease of 1% year-over-year, but a 40% sequential improvement from Q2 2020 [6][17] - Gross profit decreased by $400,000 to $35 million, with a gross margin of 71%, consistent with the same period last year [18] - Operating income decreased by 44% to $1.8 million compared to Q3 2019 [19] - Net income remained flat at $2.4 million or $0.12 per diluted share, with a slight increase in weighted average shares [20] - Adjusted EBITDA was approximately $6 million, down from $6.4 million in Q3 2019 [20] Business Line Data and Key Metrics Changes - Sales and rentals of Flexitouch systems accounted for 90% of total revenue, down from 92% in the prior year [17] - Entre Systems saw a 26% year-over-year increase in sales and rentals, contributing positively to overall revenue [6] Market Data and Key Metrics Changes - Revenue by payer in Q3 2020 was 70% commercial, 16% Medicare, and 14% VA, compared to 72%, 12%, and 16% respectively in Q3 2019 [17] - The company observed a strong recovery in privately-owned outpatient practices, particularly vascular clinics, which had fewer COVID-related restrictions [9] Company Strategy and Development Direction - The company aims to invest strategically in its business to capture the $5 billion market opportunity for lymphedema in the U.S. [25] - Continued focus on expanding the prescriber base through virtual education events and supporting existing clinicians [12][25] - The company plans to maintain a low 70% gross margin and an adjusted EBITDA margin of 7% to 8% for 2020 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the business entering Q4, despite ongoing COVID-related challenges [24] - Positive trends in patient demand and clinician engagement were noted, with expectations for gradual recovery as COVID impacts lessen [15][24] Other Important Information - The company has no outstanding borrowings and a cash position of $42.2 million, positioning it well for future investments [21][24] - The company is facing a qui tam lawsuit, with a trial expected in late Q1 or early Q2 2021 [77] Q&A Session Summary Question: What is the likelihood of improvement in Q4 given recent COVID spikes? - Management indicated that while there are uncertainties, they are optimistic based on current trends and customer feedback [31][34] Question: How has the virtual education impacted new prescriber engagement? - The company reported significant participation in virtual events, which have been effective in expanding the prescriber base [36][39] Question: Can you provide insights on the increase in prescribers? - Management noted a meaningful increase in prescribers, although they did not disclose specific numbers, emphasizing the importance of this growth for future revenue [42][43] Question: What is the status of the VA channel and sales rep access? - There has been limited change in access to VA hospitals, but the company has seen a recovery in sales through community-based outpatient centers [52][53] Question: What is the update on the qui tam lawsuit? - The company filed a motion for partial summary judgment, with a trial expected in early 2021 [77]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) (State or other juris ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q2 2020 Earnings Conference Call August 3, 2020 5:00 PM ET Company Participants Dan Reuvers – President and Chief Executive Officer Brent Moen – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Matthew O'Brien – Piper Sandler Margaret Kaczor – William Blair Chris Pasquale – Guggenheim Cecilia Furlong – Canaccord Genuity Suraj Kalia – Oppenheimer Operator Good evening, ladies and gentlemen, and welcome to the Second Quarter 2010 Earning ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37799 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q1 2020 Earnings Conference Call May 4, 2020 8:00 AM ET Company Participants Gerald Mattys - Chief Executive Officer Brent Moen - Chief Financial Officer Conference Call Participants Matthew O’Brien - Piper Sandler Companies Cecilia Furlong - Canaccord Genuity, Inc. Margaret Kaczor - William Blair & Company Christopher Pasquale - Guggenheim Partners Ryan Zimmerman - BTIG LLC Operator Please stand by. Good morning, ladies and gentlemen, and welcome to the First ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdict ...